The major NSCLC therapeutic regime based on EGFR-TKI has been evolved from gefitinib (2003), erlotinib (2004), afatinib (2013) to osimertinib (2015), all of which have greatly improved survival outcomes and prognosis for patients. Here, EGFR is linked to non-small cell lung carcinoma.